Australian experience of the SH21 flu vaccination program during the COVID-19 vaccine program

Buynder, Paul Van; A, Newbound; MacIntyre, C. Raina; Kennedy, Alexander T.; Clarke, C.; Anderson, J.

doi:10.1080/21645515.2021.1967042

Cited by 11 publications

(15 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For instance, during the 2021 Southern Hemisphere influenza season, the COVID-19 immunization program had a negative impact on SIV uptake: in Australia, a marked drop (compared with the 2019 and 2020 seasons) in coverage was reported in all age groups. The exclusion of co-administration was the likely reason for the decrease observed [27]. Unlike the Australian experience, during the ongoing 2021/2022 Northern Hemisphere SIV campaign, clinical guidelines on COVID-19/SIV co-administration have been issued by several public health authorities, including the WHO [13] and CDC [14].…”

Section: Discussionmentioning

confidence: 99%

“…Unlike the Australian experience, during the ongoing 2021/2022 Northern Hemisphere SIV campaign, clinical guidelines on COVID-19/SIV co-administration have been issued by several public health authorities, including the WHO [13] and CDC [14]. It has been suggested [27] that one of the key actions to maximize the uptake of both COVID-19 and SIV vaccines is for public health authorities to issue clear, consistent, timely and repeated communications on the importance and urgency of having both vaccinations. Our results corroborate this suggestion: among the various information sources on SIV, only people's trust in public health institutions was associated with a greater likelihood of COVID-19/SIV co-administration.…”

Section: Discussionmentioning

confidence: 99%

“…Acceptance of vaccine co-administration is driven by a variety of socio-structural, individual and contextual determinants, which should be incorporated into a tailored communication mix, in which public health institutions will play the central role. As shown by the recent Australian experience [27], correct, unambiguous, timely and multi-channel communication and training of healthcare providers in COVID-19 and SIV co-administration is essential in order to maximize the opportunity to vaccinate.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Acceptance of COVID-19 and Influenza Vaccine Co-Administration: Insights from a Representative Italian Survey

Domnich

Grassi²,

Fallani

et al. 2022

JPM

View full text Add to dashboard Cite

Co-administration of coronavirus disease 2019 (COVID-19) and seasonal influenza vaccines has several advantages, has been advocated by various public health authorities and should be seen as an opportunity to increase the uptake of both vaccines. The objective of this survey was to quantify the acceptance of concomitant COVID-19/influenza vaccination and to identify its correlates in a representative sample of Italian adults. Of 2463 participants, a total of 22.9% were favorable to vaccine co-administration, while 16.6% declared their firm unwillingness to receive both vaccines simultaneously. The remaining 60.5% of subjects could be dubbed hesitant to some degree. Compliance with the primary COVID-19 vaccination schedule (adjusted proportional odds ratio (aOR) = 7.78), previous influenza vaccination (aOR = 1.89) and trust in public health institutions (aOR = 1.22) were the main determinants of positive attitudes toward vaccine co-administration. Other significant correlates included age, sex, perceived disease severity and vaccination risk–benefit, being offered a more personalized influenza vaccine and recent seeking for influenza-related information. In Italy, hesitancy toward COVID-19/influenza vaccine co-administration is common and appears to be higher than hesitancy toward either vaccine administered alone. This pattern is multifaceted and requires specific and tailored strategies, with public health institutions playing the central role.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Acceptance of COVID-19 and Influenza Vaccine Co-Administration: Insights from a Representative Italian Survey

Domnich

Grassi²,

Fallani

et al. 2022

JPM

View full text Add to dashboard Cite

show abstract

“…These determinants should be considered when planning and rolling out future targeted health-promotion interventions to increase immunization uptake. Indeed, the last 2021 winter season in Australia saw a decrease in SIV uptake, which was possibly driven by the exclusion of co-administration strategies [ 54 ]. Analogously, policy makers should learn from the 2009 swine influenza pandemic: in the following influenza seasons, in several countries, including Italy [ 89 ] and Germany [ 90 ], a significant drop in SIV uptake was observed.…”

Section: Discussionmentioning

confidence: 99%

“…However, in some countries, such as Australia, earlier versions of these recommendations, which were issued before clinical data on vaccine co-administration became available, advised a precautionary time window of 7–14 days between COVID-19 and SIV administration. This strategy may have had some negative impact on the uptake of SIV [ 54 ].…”

Section: The Current Position Of Some Authorities On Covid-19 and Inf...mentioning

confidence: 99%

COVID-19 and Seasonal Influenza Vaccination: Cross-Protection, Co-Administration, Combination Vaccines, and Hesitancy

et al. 2022

View full text Add to dashboard Cite

SARS-CoV-2 and influenza are the main respiratory viruses for which effective vaccines are currently available. Strategies in which COVID-19 and influenza vaccines are administered simultaneously or combined into a single preparation are advantageous and may increase vaccination uptake. Here, we comprehensively review the available evidence on COVID-19/influenza vaccine co-administration and combination vaccine candidates from the standpoints of safety, immunogenicity, efficacy, policy and public acceptance. While several observational studies have shown that the trained immunity induced by influenza vaccines can protect against some COVID-19-related endpoints, it is not yet understood whether co-administration or combination vaccines can exert additive effects on relevant outcomes. In randomized controlled trials, co-administration has proved safe, with a reactogenicity profile similar to that of either vaccine administered alone. From the immunogenicity standpoint, the immune response towards four influenza strains and the SARS-CoV-2 spike protein in co-administration groups is generally non-inferior to that seen in groups receiving either vaccine alone. Several public health authorities have advocated co-administration. Different combination vaccine candidates are in (pre)-clinical development. The hesitancy towards vaccine co-administration or combination vaccines is a multifaceted phenomenon and may be higher than the acceptance of either vaccine administered separately. Public health implications are discussed.

show abstract

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults

Murdoch,

Quan,

Baber

et al. 2023

Infect Dis Ther

View full text Add to dashboard Cite

Introduction Vaccination is a critical tool for preventing coronavirus disease 2019 (COVID-19) and influenza illnesses. Coadministration of the COVID-19 vaccine, BNT162b2, with seasonal inactivated influenza vaccine (SIIV) can provide substantial benefits, including streamlining vaccine delivery. Methods In this phase 3 study, healthy 18- to 64-year-olds who had received three previous doses of BNT162b2 were randomized (1:1) to the coadministration group (month 0, BNT162b2 + SIIV; month 1, placebo) or the separate-administration group (month 0, placebo + SIIV; month 1, BNT162b2). The primary immunogenicity objective was to demonstrate that the immune responses elicited by BNT162b2 and SIIV [measured by full-length S-binding immunoglobulin G (IgG) levels and strain-specific hemagglutination inhibition assay (HAI) titers against four influenza strains 1 month post-vaccination, respectively] when coadministered were noninferior to those elicited by either vaccine administered alone, based on a prespecified 1.5-fold noninferiority margin [lower bound 95% CI for geometric mean ratio (GMR) > 0.67]. Reactogenicity and adverse event (AE) rates were evaluated. Results Randomized participants who received study vaccination ( N = 1128; coadministration group, n = 564; separate-administration group, n = 564) had a median age of 39 years. Model-adjusted GMRs for coadministration to separate administration were 0.83 (95% CI 0.77, 0.89) for full-length S-binding IgG levels and 0.89–1.00 (lower bound of all 95% CIs > 0.67) for the four influenza strain-specific HAI titers, with all endpoints achieving the prespecified noninferiority criterion. Reactogenicity events were mostly mild or moderate when BNT162b2 was coadministered with SIIV. Serious AEs were reported in < 1% of participants within 1 month after any vaccination; none were considered vaccine-related. Conclusions BNT162b2 coadministered with SIIV elicited immune responses that were noninferior to those elicited by BNT162b2 alone and SIIV alone, and BNT162b2 had an acceptable safety profile when coadministered with SIIV. The results of this study support the coadministration of BNT162b2 and SIIV in adults. Trial Registration ClinicalTrials.gov registration: NCT05310084. Supplementary Information The online version contains supplementary material available at 10.1007/s40121-023-00863-5.

show abstract

Australian experience of the SH21 flu vaccination program during the COVID-19 vaccine program

Cited by 11 publications

References 2 publications

Acceptance of COVID-19 and Influenza Vaccine Co-Administration: Insights from a Representative Italian Survey

Acceptance of COVID-19 and Influenza Vaccine Co-Administration: Insights from a Representative Italian Survey

COVID-19 and Seasonal Influenza Vaccination: Cross-Protection, Co-Administration, Combination Vaccines, and Hesitancy

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults

Contact Info

Product

Resources

About